Morgan Stanley’s PRA Health Sciences, Inc. PRAH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-213,234
| Closed | -$35.2M | – | 8278 |
|
|
2021
Q2 | $35.2M | Sell |
213,234
-344,541
| -62% | -$57.5M | ﹤0.01% | 1592 |
|
|
2021
Q1 | $85.5M | Buy |
557,775
+302,449
| +118% | +$41.1M | 0.01% | 848 |
|
|
2020
Q4 | $32M | Sell |
255,326
-239,005
| -48% | -$26.7M | ﹤0.01% | 1422 |
|
|
2020
Q3 | $50.1M | Buy |
494,331
+411,270
| +495% | +$41.9M | 0.01% | 897 |
|
|
2020
Q2 | $8.08M | Buy |
83,061
+1,277
| +2% | +$119K | ﹤0.01% | 2167 |
|
|
2020
Q1 | $6.79M | Sell |
81,784
-19,513
| -19% | -$1.9M | ﹤0.01% | 2150 |
|
|
2019
Q4 | $11.3M | Buy |
101,297
+22,726
| +29% | +$2.34M | ﹤0.01% | 2300 |
|
|
2019
Q3 | $7.8M | Sell |
78,571
-119,818
| -60% | -$11.9M | ﹤0.01% | 2382 |
|
|
2019
Q2 | $19.7M | Sell |
198,389
-141,419
| -42% | -$13.5M | 0.01% | 1501 |
|
|
2019
Q1 | $37.5M | Buy |
339,808
+91,947
| +37% | +$9.61M | 0.01% | 1005 |
|
|
2018
Q4 | $22.8M | Sell |
247,861
-216,036
| -47% | -$21.9M | 0.01% | 1356 |
|
|
2018
Q3 | $51.1M | Buy |
463,897
+140,675
| +44% | +$14.6M | 0.01% | 947 |
|
|
2018
Q2 | $30.2M | Sell |
323,222
-75,018
| -19% | -$6.46M | 0.01% | 1257 |
|
|
2018
Q1 | $33M | Buy |
398,240
+62,426
| +19% | +$5.55M | 0.01% | 1224 |
|
|
2017
Q4 | $30.6M | Buy |
335,814
+165,103
| +97% | +$13.7M | 0.01% | 1319 |
|
|
2017
Q3 | $13M | Buy |
170,711
+47,190
| +38% | +$3.57M | ﹤0.01% | 2018 |
|
|
2017
Q2 | $9.26M | Buy |
123,521
+63,978
| +107% | +$4.44M | ﹤0.01% | 2248 |
|
|
2017
Q1 | $3.88M | Sell |
59,543
-742,086
| -93% | -$43.7M | ﹤0.01% | 3132 |
|
|
2016
Q4 | $44.2M | Buy |
801,629
+679,537
| +557% | +$37.3M | 0.01% | 965 |
|
|
2016
Q3 | $6.9M | Sell |
122,092
-340,488
| -74% | -$16.7M | ﹤0.01% | 2354 |
|
|
2016
Q2 | $19.3M | Buy |
462,580
+411,824
| +811% | +$19M | 0.01% | 1452 |
|
|
2016
Q1 | $2.17M | Buy |
50,756
+26,569
| +110% | +$1.12M | ﹤0.01% | 3284 |
|
|
2015
Q4 | $1.09M | Sell |
24,187
-22,865
| -49% | -$961K | ﹤0.01% | 3984 |
|
|
2015
Q3 | $1.83M | Sell |
47,052
-49,285
| -51% | -$1.97M | ﹤0.01% | 3596 |
|
|
2015
Q2 | $3.5M | Sell |
96,337
-68,261
| -41% | -$2.16M | ﹤0.01% | 3122 |
|
|
2015
Q1 | $4.75M | Buy |
164,598
+37,640
| +30% | +$1.05M | ﹤0.01% | 2806 |
|
|
2014
Q4 | $3.08M | Buy |
+126,958
| New | +$2.86M | ﹤0.01% | 3184 |
|
Other funds holding PRAH
Morgan Stanley's PRAH Position: Q3 2021 in Review
Morgan Stanley sold out of PRA Health Sciences, Inc. (PRAH) in Q3 2021, closing a stake of 213,234 shares — an estimated $35.2M sold.
Morgan Stanley first reported a position in PRAH in Q4 2014 and held it in 27 quarters. The position peaked at $85.5M in Q1 2021. 1 fund tracked by Wall St. Rank holds PRAH as of Q3 2021.
- Morgan Stanley reported no remaining PRA Health Sciences, Inc. position as of Q3 2021 after selling out during the quarter.
- Morgan Stanley sold 213,234 PRA Health Sciences, Inc. shares in Q3 2021, an estimated $35.2M.
- Morgan Stanley first reported a position in PRA Health Sciences, Inc. in Q4 2014 and held it in 27 quarters.
- Morgan Stanley's PRA Health Sciences, Inc. position peaked at $85.5M in Q1 2021.
- 1 fund tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q3 2021.
Based on Morgan Stanley's 13F filing for Q3 2021, filed 15 Nov 2021.